Breaking News, Collaborations & Alliances

MorphoSys, Xencor Enter Antibody Pact

MorphoSys AG and Xencor, Inc. have signed an exclusive worldwide license and collaboration agreement for an antibody in Phase I development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG and Xencor, Inc. have signed an exclusive worldwide license and collaboration agreement for an antibody in Phase I development. Under the agreement, MorphoSys has an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies. The companies will collaborate on the Phase I trial in patients with chronic lymphocytic leukemia (CLL), for which Xencor will continue to carry the costs under its development plan. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters